1	A randomized controlled safety and feasibility trial of floatation-REST in anxious
2	and depressed individuals
3	
4	
5	
6	
7 8 9 10	McKenna M. Garland, M.A. ^{a,b} , Raminta Wilson, M.D., M.P.H. ^a , Wesley K. Thompson, Ph.D. ^a , Murray B. Stein, M.D., M.P.H. ^{c,d,e} , Martin P. Paulus, M.D. ^{a f,} , Justin S. Feinstein, Ph.D. ^{a,f,g} , Sahib S. Khalsa, M.D., Ph.D. ^{a,f,g}
11	
12	
13 14 15 16 17 18 19 20 21 22 23 24	^a Laureate Institute for Brain Research, University of Tulsa, Tulsa, Oklahoma ^b Kendall College of Arts and Sciences, University of Tulsa, Tulsa, Oklahoma ^c Department of Psychiatry, University of California San Diego, La Jolla, California ^d Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California ^e Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego, California ^f Oxley College of Health Sciences, University of Tulsa, Tulsa, Oklahoma ^g Float Research Collective, Kihei, Hawaii
25	*Corresponding author: Sahib S. Khalsa, M.D., Ph.D. skhalsa@laureateinstitute.org
26	
27	
28	
29	
30	
31	

1.

\mathbf{a}
1

Abstract

33	Background: Reduced Environmental Stimulation Therapy via floatation (floatation-REST) is a
34	behavioral intervention designed to attenuate exteroceptive sensory input to the nervous system.
35	Pilot studies in anxious and depressed individuals demonstrated that single sessions of floatation-
36	REST are safe, well-tolerated, and associated with acute anxiolysis. However, there is not
37	sufficient evidence of the feasibility of floatation-REST as a repeated intervention.
38	Methods: We randomized 75 individuals with anxiety and depression to six sessions of
39	floatation-REST in different formats (pool-REST or pool-REST preferred) or an active
40	comparator (chair-REST). Feasibility was assessed via adherence rate to the assigned
41	intervention, tolerability via duration of REST utilization and overall study dropout rate, and
42	safety via incidence of serious or non-serious adverse events.
43	Results: Six-session adherence was 85% for pool-REST, 89% for pool-REST preferred, and 74%
44	for chair-REST. Dropout rates did not differ significantly between the treatment conditions.
45	Mean session durations were consistently above 50 minutes, and when allowed to choose the
46	duration and frequency, participants opted to float for an average of 75 minutes. There were no
47	serious adverse events associated with any intervention. Positive experiences were endorsed
48	more commonly than negative ones and were also rated at higher levels of intensity.
49	Conclusions: Taken together, six sessions of floatation-REST appear feasible, well-tolerated, and
50	safe in anxious and depressed individuals. Floatation-REST induces positively-valenced
51	experiences with few negative effects. Larger randomized controlled trials evaluating markers of
52	clinical efficacy are warranted.

53 Clinical Trial Registration Identifier: NCT03899090

3

54

Introduction

55 Reduced Environmental Stimulation Therapy via floatation (i.e., floatation-REST) is a 56 behavioral intervention designed to systematically attenuate exteroceptive sensory input to the 57 nervous system. Dating back to the 1950's, REST was first introduced to assess how humans 58 would react to low-level or monotonous stimulation of the nervous system, with subsequent 59 investigations exploring REST as a therapeutic intervention for habit modification during 60 smoking cessation or stress reduction [1]. The earliest forms of REST involved strict 61 confinement to a bed in a dimly lit cubicle for days at a time (i.e., 'chamber-REST') [2] or full-62 body submersion in a vertical water tank with the assistance of a breathing helmet [3, 4]. Since 63 then, several technological developments have considerably expanded the availability of 64 different REST formats. Currently, the most common form of floatation-REST involves floating 65 effortlessly in a shallow pool of water heated to skin temperature and saturated with Epsom salt 66 to increase buoyancy (consequently, it is sometimes also called 'pool-REST'). The environment is specially engineered to be lightproof, soundproof, and humidity and temperature-controlled, so 67 68 that input from visual, auditory, olfactory, gustatory, thermal, tactile, vestibular, and 69 proprioceptive channels is minimized, as is movement and speech [5]. Chair-REST has also 70 emerged as an alternative form of REST [6, 7]. In this environment, individuals recline in an 71 ergonomically engineered chair designed to take pressure off the spinal cord. Typically, these 72 chairs are placed in dimly lit and quiet rooms, similar but not identical to what would be 73 experienced during pool-REST. Our previous work has highlighted that although the degree of 74 sensory attenuation of chair-REST is not as substantial as traditional pool-REST, single sessions 75 of chair-REST can produce effects on negative affect, anxiety, stress, relaxation, serenity, and 76 refreshment of a similar nature in clinically anxious individuals [7]. Additionally, chair-REST

4

induced a similar though weaker pattern of neural changes in resting state functional connectivity
as pool-REST [6]. Such "zero-gravity chairs" have garnered public attention and are now
available in many large department and furniture stores. The availability and utilization of poolREST has grown in recent years, with hundreds of recreational "float centers" opening across the
world during the past decade [8]. Despite the increase in public interest and consumption of
various forms of REST, there has been limited research investigating the feasibility of the
technique, especially in clinical populations.

84 Preliminary insights into the tolerability and safety of floatation-REST in anxious and 85 depressed individuals are restricted to a few studies. A wait-list control trial reported that 86 individuals scoring high on self-reported measures of generalized anxiety were largely adherent 87 to 12 sessions of floatation-REST [9]. Another study found that individuals with stress-related 88 pain and burnout depression were able to complete up to 33 sessions of floatation-REST [10]. 89 However, neither of these studies assessed adverse events that could have arisen during the 90 repeated sessions of floatation-REST, nor did they formally evaluate intervention feasibility. In 91 prior studies, most anxious individuals who were assigned fixed durations of pool-REST or 92 chair-REST for 45 to 90 minutes in length tolerated this amount [5, 7, 9, 11], but the impact of 93 flexible assignment on preference has not been investigated. Finally, our initial safety studies 94 examining the effects of single sessions of pool-REST or chair-REST in clinically anxious 95 individuals revealed no serious adverse events, suggesting that the brief intervention exposure 96 was safe and well-tolerated [5, 7]. Regarding safety, it is important to note that there have been 97 several deaths reported with the use of floatation tanks at recreational float centers associated 98 with concurrent drug (i.e., ketamine) or alcohol use [12], suggesting the need for inclusion of 99 substance use screening. There have also been reports of auditory and visual hallucinations

5

during floatation-REST [13]. However, these are generally described in a positive light, and are infrequent [1, 5]. Other negative events that have been reported include occasional skin itchiness or dry mouth, as well as discomfort resulting from accidental introduction of saltwater to the eyes or open cuts [5, 14]. Despite the common utilization of floatation-REST by the public, and an emerging clinical trials literature, no studies have systematically evaluated the safety profile of this intervention across multiple sessions.

106 This study examined the feasibility, tolerability, and safety of floatation-REST as a 107 repeatable intervention in clinically anxious and depressed individuals using a randomized 108 design with an active comparator (chair-REST). Our primary outcome was feasibility. We 109 hypothesized that feasibility would be reflected by 6-session adherence rates of 80% or above, a 110 level similar to standard behavioral interventions for anxiety and depression [15, 16]. As an 111 additional feasibility assessment, we evaluated for potential differences in credibility and 112 expectancy between the assigned REST interventions. We predicted that all forms of floatation-REST would be well-tolerated, with low dropout rates (<20%) over the course of the 113 114 intervention and 6-month follow-up period. We also predicted that individuals would remain in 115 their assigned REST environment for the majority of the allotted duration of time. Based on the 116 prior literature, we predicted that the REST interventions would be safe and associated with 117 minimal adverse reactions. Finally, as an exploratory aim, we examined the impact of flexible 118 assignment on floatation-REST preference in terms of the chosen frequency and duration of float 119 sessions, in order to provide information to help optimize the design of future trials.

6

120

Methods

121 Participant Recruitment

122 75 treatment-seeking adults with anxiety and depression were recruited through the Laureate 123 Institute for Brain Research's participant databases ([17] see Supplement for sample size 124 determination). Inclusion criteria included high levels of current anxiety (as measured by an 125 OASIS score ≥ 6 ; [18]) and anxiety sensitivity (as measured by an ASI-3 score ≥ 24 ; [19]). Of 126 note, the initial eligibility criteria of OASIS score ≥ 8 and ASI-3 score ≥ 29 were lowered in 127 September 2020 to increase participant recruitment to meet the targeted rate specified in the 128 funded grant. Depression symptoms were measured via the Patient Health Questionnaire (PHQ-129 9, [20]), but an inclusion cutoff score was not specified. Other inclusion criteria included: age 130 between 18 and 60 years, and either no prior experience of floatation-REST or a minimum of 1 131 year since the last float session. If taking psychiatric medications or receiving psychotherapy, the 132 treatment regimen was required to be stable, defined as having taken the medication or been in 133 therapy for 8 weeks or longer. Daily benzodiazepine use was exclusionary. Participants taking 134 benzodiazepines or opioids on an as-needed basis had to be willing to abstain from use within 24 135 hours of each float session. Other exclusion criteria included uncomfortability in water or 136 receiving blood draws, any skin conditions or open wounds that could cause pain when exposed 137 to saltwater, diagnosis of a neurological disorder (e.g., epilepsy), a comorbid diagnosis of bipolar 138 disorder, schizophrenia, or an eating disorder, active suicidality with plan or intent, receiving 139 current inpatient psychiatric treatment, or moderate to severe substance use disorder (as 140 determined by the MINI 7.0). Evidence of current drug use was also assessed prior to each 141 floatation-REST session via urine drug screen testing for amphetamines, methamphetamines, 142 cocaine, barbiturates, benzodiazepines, methylenedioxymethamphetamine (MDMA), methadone,

7


opiates, oxycodone, phencyclidine, propoxyphene, and ketamine, and breathalyzer testing for
alcohol; a positive readout on any of these tests was exclusionary. Pregnancy was exclusionary
based on a positive urine pregnancy test. All study procedures were approved by the local ethics
committee (Western Institutional Review Board Protocol #: 20150528) and were performed in
accordance with Declaration of Helsinki. All participants provided their written informed
consent prior to participation and were compensated for their study involvement. The study was
pre-registered on ClinicalTrials.gov (NCT03899090).

- 150
- 151 Experimental Design and Procedures

152 Using a randomized parallel study design, participants completed a total of 11 visits. The 153 study visit timeline is outlined in Figure 1. Participants initially completed a brief telephone 154 screen to collect demographic information and evaluate potential study eligibility. During visit 1, 155 official study eligibility was determined using the inclusion/exclusion criterion. After providing 156 informed consent, participants returned for visit 2, where baseline symptom ratings were 157 completed via clinician-reported and self-reported scales, and some behavioral testing of cardiac 158 interoception (results to be reported separately). Visit 2 concluded by unblinding and informing 159 the participant of their randomized (1:1:1) assignment to one of three intervention conditions: 160 pool-REST, pool-REST preferred, or chair-REST (i.e., the active comparator, described further 161 below). The randomization schedule was pre-determined by a statistical consultant uninvolved in 162 the study before participant recruitment and stored as a blinded electronic list. At the time of 163 assignment, the study coordinator would unblind and reveal the participant's allocation. At the 164 start of visit 3, all participants completed the Credibility/Expectancy Questionnaire (CEQ; [21]), 165 to assess their pre-intervention attitudes towards the assigned intervention arm. Participants then

8

166	completed six sessions (visits 3-8) according to their assigned condition. We assessed serious
167	and non-serious adverse events after each session via a detailed survey of positive and negatively
168	valenced experiences using a scale drawn from our prior floatation-REST study [5] and via
169	verbal self-report throughout the study period. Following the sixth and final session (visit 8),
170	participants returned to the lab for a post-intervention session (visit 9), where clinician-reported
171	and self-reported symptom ratings were once again collected and behavioral testing of cardiac
172	interoception was completed. The same clinician and self-reported symptom scales were
173	completed again at 6-week (visit 10) and 6-month (visit 11) follow-up visits. Follow-up surveys
174	were initially administered in the laboratory via an electronic tablet, but due to the Covid-19
175	pandemic these were switched to remote visits starting in May 2020. All surveys were obtained
176	electronically using REDCap (Research Electronic Data Capture; Version 10.6.19; [22, 23]).
177	



STUDY TIMELINE

10

182 Experimental Conditions

183 *Pool-REST*. The pool-REST condition, which was delivered at the Laureate Institute for Brain 184 Research facility, involved prescribed (i.e., fixed) session durations and inter-session intervals 185 within an open or enclosed circular float pool (Floataway Inc., Norfolk, United Kingdom). 186 Participants were instructed to complete 1-hour float sessions once per week for six weeks. Each 187 pool measured 2.44 meters in diameter and 0.28 meters in depth. The water in each pool was 188 saturated with over 800 kilograms of Epsom salt (magnesium sulphate), creating a specific 189 gravity of approximately 1.26. This dense salt-water solution allowed for participants to float 190 effortlessly in a supine position. Both pools were constructed in rooms designed to be lightproof 191 and soundproof. The air and water temperature of each room was also calibrated to match the 192 temperature of the skin surface (~35.0 degrees Celsius). More details about how the pool-REST 193 condition was specially engineered to minimize all manner of external sensory stimulation can 194 be found in Feinstein et al., 2018a. We allowed participants to choose between the open and 195 enclosed pool to provide some flexibility for preference and to facilitate the optimal flow of 196 participants through the study.

197

Pool-REST Preferred. The pool-REST preferred condition involved increased flexibility of both the session duration and the frequency. Participants were instructed that they were to complete six sessions in the open or closed pool, but they were allowed to freely set their float duration for up to two hours per session. In addition, they were permitted to choose the frequency of their floating schedule, such that they could float as often as they preferred within a 12-week period, with the only requirement being that there needed to be a minimum of 24 hours between sessions.

11

205

206 *Chair-REST.* During chair-REST, which was delivered at the Laureate Institute for Brain 207 Research facility, participants reclined in a Zero Gravity Chair (PC510, Classic Power, Series 2, 208 Human Touch Inc., Long Beach, CA). This active comparator condition was tailored to closely 209 match the pool-REST condition on many parameters including a supine body position, the same 210 prescribed session duration and inter-session interval (i.e., 1-hour sessions completed once per 211 week for six weeks) in a room with reduced light and sound, and a similar instruction set 212 emphasizing the importance of stillness and wakefulness throughout each session (see 213 Supplemental Materials for full instruction set). Participants were informed that the chair was 214 ergonomically designed to take pressure off the spinal cord and used memory foam backing to 215 help the chair conform to each participant's body shape. To match the instruction set across 216 REST conditions, the Zero Gravity chair was explicitly referred to as the "float chair" and the act 217 of lying in the chair was referred to as "floating." The chair was placed in a dark and quiet room, 218 although the degree of light and sound attenuation was not as strong as that delivered in the pool 219 conditions (i.e., participants could perceive a low-level of external sound and light). Unlike the 220 pool conditions, the ambient temperature was maintained at a normal room temperature of ~ 23.3 221 degrees Celsius, so participants randomized to the chair-REST condition remained fully clothed 222 during each session.

223

224 Measures

Events Assessment — A 43-item self-report measure ([5]; see Supplemental Material) was used
 to assess safety and subjective experiences occurring in each float session. This checklist was
 adapted from our previous pilot studies and was designed to assess potential adverse experiences

12

228 associated with floatation-REST. 29 of the 43 items assessed the presence of negative physical or 229 psychological events including itchiness, dry mouth, pain, anxiety/panic, flashbacks, suicidality, 230 and hallucinations, as well as the presence of positive experiences (e.g., heightened feelings of 231 joy, refreshment, serenity); these 14 items were included to reduce response biases, as well as to 232 prevent a sole focus on assessing negative experiences associated with REST. Each item was 233 rated on four-point scale ("none," "mild," "moderate," or "extreme") using the following 234 instructions: "Did you notice or experience an increase in any of these items during or shortly 235 after your float today? Please only mark items that showed an increase from your typical day-to-236 day experience." For any item that had an endorsement other than "None," participants were 237 provided a free-response box to describe their experience in more detail. For certain negative 238 symptoms (strong emotional memories, flashbacks, heightened thoughts related to death, visual 239 or auditory hallucinations, out-of-body experiences, feelings of detachment, loss of control over 240 behavior, and flight of ideas/racing thoughts) receiving any endorsement other than "None" 241 prompted participants with the following question: "Overall, was this a positive or negative 242 *experience?*" [5]. Items rated as "none" were coded as 0, negatively experienced items ranged 243 from -3 ("extremely negative") to -1 ("mildly negative"), and positively experienced items 244 ranged from 1 ("mildly positive) to 3 ("extremely positive").

245

Credibility/Expectancy Assessment — The Credibility/Expectancy Questionnaire (CEQ; [21])
was used to measure attitudes about treatment feasibility. The CEQ is a 6-item self-report
measure with individual items rated on a 1-9 or a 0%-100% scale. Items assess attitudes about
"how believable, convincing, and logical a treatment is" (i.e., credibility; [24]), and expectations
one holds about how the treatment might influence symptoms (i.e., expectancy).

13

75	1	
23	T	

There were no changes to the primary outcome or the main secondary outcomes reported in the current study. A number of additional secondary outcomes were specified in May, 2022, prior to analysis of the data, and will be included in a separate report.

255

Statistical Analysis

256 Feasibility

257 The primary outcome of feasibility was assessed by calculating adherence to the assigned 258 sessions via the formula $\hat{p} = \sum_{i=1}^{n} p_i / n$, where p_i was the proportion of completed sessions (out 259 of 6) for subject *i* and *n* was the number of subjects per condition (i.e., 25). To measure 260 attitudinal aspects of feasibility, pre-treatment credibility beliefs were calculated by taking the 261 mean of the first three items of the CEO [25], while expectancy beliefs were captured via a 262 single item rated on a 0 to 100% scale assessing how much improvement in their symptoms the 263 participant thought would occur after completing the assigned intervention. Two separate one-264 way ANOVAs were performed to assess for between-group differences in pre-intervention 265 credibility and expectancies, respectively.

266

267 Tolerability

Tolerability was assessed in three ways; first, by calculating the overall dropout rate for each condition (i.e., (number of subjects who withdrew from the study or who were lost to followup)/25). Secondly, a Kaplan-Meier analysis with post-hoc log-rank tests was used to test for differential dropout rates over time for the three assigned conditions [26]. Third, within-session tolerability was assessed by fitting a linear mixed models (estimated using REML and the nloptwrap optimizer) to predict the duration of each session with visit and condition as fixed

14

274	effects (formulas: Session Duration (in minutes) ~ Visit * Condition). The model included
275	subject ID as a random effect (formula: ~1 Subject ID) and utilized an AR1 covariance
276	structure. Post-hoc two-sided t-tests with Holm corrections were used to interpret significant
277	main effects, as well as simple effects for all significant interactions.
278	
279	Safety
280	The number of adverse and serious adverse events and their relationship to the intervention were
281	recorded over the course of the entire study, including during the follow-up period. We then fit a
282	linear mixed model (estimated using REML and the nloptwrap optimizer) to predict event
283	magnitude ratings with event, visit, and condition parameters (formulas: Event Intensity Rating ~
284	Event * Visit * Condition). The models included subject ID and visit as random effects (formula:
285	~1 Subject ID/Visit) and utilized an AR1 covariance structure. Post-hoc two-sided t-tests with
286	Holm corrections (Holm, 1979) were used to interpret significant main effects, as well as simple
287	effects for all significant interactions. All analyses were performed in RStudio (Version 3.6.0;
288	[27]).
289	
290	Pool-REST Preferred
291	The impact of flexible assignment on preferred frequency of floating for the pool was
292	measured by calculating the average number of days between float sessions and the
293	corresponding standard deviation. To assess whether session frequency in this condition was
294	related to baseline severity of anxiety, depression, and anxiety sensitivity symptoms, we
295	examined bivariate correlations between float frequency and baseline OASIS, PHQ-9, and ASI-3

scores. Additionally, we examined bivariate correlations between the average session duration

15

297 (in minutes) for each intervention and baseline measures of symptom severity (i.e., OASIS,

298 PHQ-9, and ASI-3).

299

Results

300 Participant Characteristics

301 Recruitment occurred between February 2019 and October 2021, with a four month 302 pause starting March 2020 during the Covid-19 pandemic and was terminated upon achievement 303 of the recruitment target. Sociodemographic and clinical characteristics for the 75 individuals 304 who were randomized to each intervention arm are summarized in Table 1. A CONSORT 305 diagram reflecting the flow of participants in each arm is shown in Figure 2. One-way ANOVAs 306 revealed that the groups did not differ significantly on age, education, medication status (i.e., 307 number of psychotropic medications), BMI, or baseline OASIS, ASI-3, or PHQ-9 scores. Chi-308 squared tests indicated that there were no significant differences between the conditions 309 regarding sex, race/ethnicity, or the frequency of clinical diagnosis or rate of psychotherapy 310 utilization. Most of the sample identified as non-Hispanic White (81.3%). The most common 311 psychiatric diagnosis in the sample was major depressive disorder (97.3%) followed by 312 generalized anxiety disorder (50.7%).

313

Table 1. Participant Demographics, DSM-5 Diagnostic Comorbidities, and Screening Scores at
 Study Entry

	Chair-REST (n=25)	Pool-REST (n=25)	Pool-REST preferred (n=25)	F	df	р
Demographics						
Sex				$\chi^2 = 0.15$	2	0.93
Male, N (%)	6 (24%)	6 (24%)	5 (20%)			
Female, N (%)	19 (76%)	19 (76%)	20 (80%)			
Age	37.8 (13.4)	33.4 (11.7)	34.3 (9.0)	1.01	72	0.37
Years of Education	15.2 (1.3)	15.1 (1.8)	15.8 (1.7)	1.15	71	0.32

16

Psychiatric Medications ^a 0.7 (1.1) 0.3 (0.6) 1.0 (1.3) 3.00 72 0.06 Receiving Psychotherapy, N(%) 11 (44) 11 (44) 16 (64) $\chi^2 = 2.67$ 2 0.26 Race/Ethnicity, N(%) 22 (88) 20 (80) 19 (76) $\chi^2 = 8.75$ 10 0.56 White/Caucasian 22 (88) 20 (80) 19 (76) $\chi^2 = 8.75$ 10 0.56 Black/African American 2 (1) 6 (24) 4 (16) $\chi^2 = 8.75$ 10 0.56 Am. Indian/Alaskan Native 5 (20) 5 (20) 4 (16) $\chi^2 = 8.75$ 10 0.56 Asian/Pacific Islander 1 (4) 0 (0) 0 (0) 0 (0) 10 (0) 10 (0) 10 (0) 11 (4) 2 (8) 2 (8) 500 (0)	BMI	29.3 (7.3)	28.8 (5.1)	27.9 (6.9)	0.30	70	0.74
Race/Ethnicity, N(%) $\chi^2 = 8.75 \ 10$ 0.56White/Caucasian22 (88)20 (80)19 (76)Black/African American2 (1)6 (24)4 (16)Am. Indian/Alaskan Native5 (20)5 (20)4 (16)Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report MeasuresOASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78 \ 8$ 0.88Major depressive disorder24 (96)24 (96)25 (100)Generalized anxiety disorder9 (36)12 (48)8 (32)7 (28)11.44	Psychiatric Medications ^a				3.00	72	0.06
Race/Ethnicity, N(%) $\chi^2 = 8.75$ 100.56White/Caucasian22 (88)20 (80)19 (76)Black/African American2 (1)6 (24)4 (16)Am. Indian/Alaskan Native5 (20)5 (20)4 (16)Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report MeasuresOASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78$ 0.88Major depressive disorder24 (96)24 (96)25 (100)25 (100)60.88Generalized anxiety disorder9 (36)12 (48)8 (32)7 (28)11.44	Receiving Psychotherapy, N(%)			· · · ·	$\chi^2 = 2.67$	2	0.26
White/Caucasian22 (88)20 (80)19 (76)Black/African American2 (1)6 (24)4 (16)Am. Indian/Alaskan Native5 (20)5 (20)4 (16)Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report MeasuresOASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Q ² = 3.7880.88Major depressive disorder24 (96)24 (96)25 (100)211. (44)Social anxiety disorder9 (36)12 (48)8 (32)53.1214.44Social anxiety disorder9 (36)12 (48)8 (32)14.44	Race/Ethnicity, N(%)						0.56
Black/African American Am. Indian/Alaskan Native2 (1)6 (24)4 (16)Am. Indian/Alaskan Native5 (20)5 (20)4 (16)Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report MeasuresOASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76 $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)25 (100)25 (100)Generalized anxiety disorder9 (36)12 (48)8 (32)4 (28)Posttraumatic stress disorder9 (36)8 (32)7 (28)	White/Caucasian	22 (88)	20 (80)	19 (76)			
Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report Measures $0 (0)$ 0 (0)2 (8)OASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100) $\chi^2 = 3.78$ 80.88Major depressive disorder9 (36)12 (48)8 (32)9 (28)11.64411.644Social anxiety disorder9 (36)12 (48)8 (32)7 (28)11.64411.644	Black/African American	2 (1)	6 (24)				
Asian/Pacific Islander1 (4)0 (0)0 (0)Hispanic1 (4)2 (8)2 (8)Unspecified0 (0)0 (0)2 (8)Self-Report Measures $0 (0)$ 0 (0)2 (8)OASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100) $\chi^2 = 3.78$ 80.88Major depressive disorder9 (36)12 (48)8 (32)9 (28)11 (44)11 (44)Social anxiety disorder9 (36)8 (32)7 (28)11 (44)11 (44)11 (44)	Am. Indian/Alaskan Native						
Hispanic Unspecified1 (4) 0 (0)2 (8)2 (8)Self-Report Measures0 (0)0 (0)2 (8)Self-Report Measures10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100)Generalized anxiety disorder10 (40)17 (68)11 (44)Social anxiety disorder9 (36)12 (48)8 (32)Posttraumatic stress disorder9 (36)8 (32)7 (28)	Asian/Pacific Islander						
Self-Report MeasuresOASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76 Psychiatric Diagnosis , N(%) ^b Major depressive disorder24 (96)24 (96)25 (100)Generalized anxiety disorder10 (40)17 (68)11 (44)Social anxiety disorder9 (36)12 (48)8 (32)Posttraumatic stress disorder9 (36)8 (32)7 (28)	Hispanic		2 (8)	2 (8)			
OASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76 Psychiatric Diagnosis , N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100) $\chi^2 = 3.78$ 80.88Social anxiety disorder9 (36)12 (48)8 (32)7 (28)11144	Unspecified						
OASIS Anxiety10.1 (2.5)9.4 (2.8)9.9 (2.5)0.53690.59ASI-3 Anxiety Sensitivity35.6 (13.0)39.9 (9.4)40.5 (11.8)0.04690.97PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76 Psychiatric Diagnosis , N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100) $\chi^2 = 3.78$ 80.88Social anxiety disorder9 (36)12 (48)8 (32)7 (28)10.4410.44	Self-Report Measures						
PHQ-9 Depression12.5 (4.9)11.5 (5.5)12.1 (4.7)0.28690.76 Psychiatric Diagnosis , N(%) ^b $\chi^2 = 3.78$ 80.88Major depressive disorder24 (96)24 (96)25 (100)Generalized anxiety disorder10 (40)17 (68)11 (44)Social anxiety disorder9 (36)12 (48)8 (32)Posttraumatic stress disorder9 (36)8 (32)7 (28)	-	10.1 (2.5)	9.4 (2.8)	9.9 (2.5)	0.53	69	0.59
Psychiatric Diagnosis, N(%) ^b $\chi^2 = 3.78$ 0.88 Major depressive disorder 24 (96) 25 (100) Generalized anxiety disorder 10 (40) 17 (68) 11 (44) Social anxiety disorder 9 (36) 12 (48) 8 (32) Posttraumatic stress disorder 9 (36) 8 (32) 7 (28)	ASI-3 Anxiety Sensitivity	35.6 (13.0)	39.9 (9.4)	40.5 (11.8)	0.04	69	0.97
Major depressive disorder 24 (96) 24 (96) 25 (100) Generalized anxiety disorder 10 (40) 17 (68) 11 (44) Social anxiety disorder 9 (36) 12 (48) 8 (32) Posttraumatic stress disorder 9 (36) 8 (32) 7 (28)	PHQ-9 Depression	12.5 (4.9)	11.5 (5.5)	12.1 (4.7)	0.28	69	0.76
Major depressive disorder 24 (96) 24 (96) 25 (100) Generalized anxiety disorder 10 (40) 17 (68) 11 (44) Social anxiety disorder 9 (36) 12 (48) 8 (32) Posttraumatic stress disorder 9 (36) 8 (32) 7 (28)	Psychiatric Diagnosis , N(%) ^b				$\chi^2 = 3.78$	8	0.88
Social anxiety disorder9 (36)12 (48)8 (32)Posttraumatic stress disorder9 (36)8 (32)7 (28)	Major depressive disorder	24 (96)	24 (96)	25 (100)			
Posttraumatic stress disorder 9 (36) 8 (32) 7 (28)	ů i	10 (40)	17 (68)	11 (44)			
	Social anxiety disorder	9 (36)	12 (48)	8 (32)			
Panic disorder 3 (12) 6 (24) 7 (28)	Posttraumatic stress disorder	9 (36)	8 (32)	7 (28)			
	Panic disorder	3 (12)	6 (24)	7 (28)			

316 *Note.* Numbers reflect means and standard deviation unless otherwise indicated. BMI = Body

317 Mass Index; OASIS = Overall Anxiety Severity and Impairment Scale [18] measured at pre-

318 intervention visit; ASI-3 = Anxiety Sensitivity Index-3 [19], measured at pre-intervention visit;

319 PHQ-9 = Patient Health Questionairre-9 [20] measured at pre-intervention visit. ^aNumbers

320 reflect the mean number of prescribed psychiatric medications taken by the participant, measured

321 at the initial screening. ^bDiagnosis was determined by clinician interview using the MINI version


322 7.0 [28]. For brevity, only comorbid diagnoses with frequency > 10% across the entire sample (n

323 = 75) are listed. As this study allowed for comorbid diagnoses, percentage totals will be > 100%.

324

17

326 *Figure 2. CONSORT Diagram.* Note. C = Completed. W = Withdrew.



328


327

329 Feasibility

330Average treatment adherence was 89% (5.31.6 sessions) for the pool-REST preferred331condition, 85% (5.11.8 sessions) for the pool-REST condition, and 74% (4.42.5 sessions)

- 332 for the chair-REST condition. One-way ANOVAs revealed that the REST conditions did not
- differ significantly on pre-intervention CEQ credibility (F(2, 67) = 2.42, p = 0.097) or
- expectancy (F(2, 67) = 0.98, p = 0.379; see Figures 3a-3b). The average credibility score for the
- three groups was 6.67 ± 1.50 . On average, the three groups expected the intervention to halve
- 336 their symptoms $(50.3 \pm 21.6\%)$.
- 337
- 338

Figure 3. Pre-Treatment Credibility Beliefs and Expectations for Symptom Improvement. *Note.*Figures reflect pre-intervention ratings for credibility of beliefs (top) and expectations for
symptom improvement (bottom) on the Credibility and Expectancy Questionnaire, according to
the assigned intervention. The black dots and error bars represent the mean and standard error of
the mean, respectively. Grey dashed lines reflect an established average for credibility and
expectancy beliefs of other non-pharmacological treatments (e.g., psychotherapy, see
discussion). There were no significant group differences in levels of pre-treatment credibility or
expectancy beliefs (*ps* > .05).





20

348

349 Tolerability

350	The Kaplan-Meier survival analyses did not indicate a significant difference in treatment
351	dropout among the three groups ($p = .40$, Figure 4). Following the randomization at the baseline
352	visit, the chair-REST condition had the highest dropout rate at 16% ($n = 4$ individuals), versus
353	4% (n = 1 individual) for the pool-REST condition and 0% for the pool-REST preferred
354	condition. Across the six-session intervention, the chair-REST condition demonstrated an overall
355	dropout rate of 32%, while the pool-REST condition dropout rate was 24%, and the pool-REST
356	preferred dropout rate was 16%. The dropout rate at the 6-month follow up was 36% for the
357	chair-REST condition, 28% for the pool-REST condition, and 20% for the pool-REST preferred
358	condition (1 individual dropped out from each of the groups).






21

363 Of note, due to the onset of the Covid-19 pandemic and mandatory shutdowns, two 364 participants were withdrawn from the study by the study investigators. One participant in the 365 Chair-REST condition was withdrawn from the study after session 2 (at day 27), and one 366 participant from the Pool-REST condition was withdrawn following their fifth session (at day 367 73). This dropout information was entered into the analysis, but due to the small amount of 368 dropout and no discernable group pattern, no further corrective action was taken during the 369 analysis. 370 The linear mixed effects analysis of within-session tolerability (i.e., session duration; Figure 5), revealed a main effect of condition (F(2) = 10.33, p < .001, $\eta_p^2 = .24$), such that 371 372 session durations were significantly longer for the pool-REST preferred condition ($M = 75.4 \pm$ 373 29.4 minutes) than either the chair-REST ($M = 58.4 \pm 4.3$ minutes; p = .007, d = .810) or pool-374 REST condition (M = 53.0 + 12.3 minutes; p = .0002, d = .996). There were no statistically 375 significant differences in session duration between the chair-REST and pool-REST conditions (p 376 = .292). Across the 373 REST sessions administered across the entire study, 317 sessions (85%) 377 of total) were 50 minutes or longer in duration. 378

22

380 Figure 5. Session durations. Note. Session durations were significantly longer for the pool-

- 381 REST preferred condition than either the chair-REST (p = .007) or pool-REST conditions (p =
- 382 .0002). There were no statistically significant differences in session duration between the chair-
- 383 REST and pool-REST conditions (p = .292). Duration did not vary as a function of session.



384


385 Safety

386 Four adverse events were recorded during the study. All were determined to be unrelated 387 to the study intervention. One participant in the chair-REST condition reported two separate 388 instances of migraines with nausea on the days of their first and second REST session. One 389 participant in the pool-REST condition who suffered from seasonal allergies reported an ear 390 infection four days after their third REST session. Finally, one participant in the pool-REST 391 condition reported a suicide attempt the night before their 6-week follow-up visit. The participant 392 was subsequently evaluated at a local psychiatric emergency department, where it was 393 determined that hospital admission was unwarranted.

394	Regarding the acutely experienced event profile, Figure 6 shows the average magnitude
395	rating for each event across the three assigned REST conditions. A qualitative inspection of the
396	data revealed that positive experiences were endorsed more commonly than negative ones and
397	were also rated at higher levels of intensity, with average intensity ratings in the mild-to-
398	moderate range for positive experiences and well-below mild for negative experiences. In the
399	linear mixed effects (LME) quantitative analysis of intensity ratings, we observed a significant
400	main effect of event (F(43) = 153.61, $p < .001$, $\eta_p^2 = .30$) and treatment condition (F(2) = 3.51, p
401	= .04, η_p^2 = .09), which was accounted for by the significant interaction between these variables
402	(F(86) = 6.43, $p < .0001$, $\eta_p^2 = .04$). Post-hoc comparisons suggested that feelings of intense
403	joy/happiness, increased energy, increased ability to focus/concentrate, serenity and
404	peacefulness, appreciation for life, refreshment, relaxation, silent mind, pain-free existence, and
405	feelings of flow were experienced more positively in the pool-REST and pool-REST preferred
406	conditions when compared to the chair-REST condition ($ps < .05$). Stronger positive ratings for
407	the pool-REST preferred condition were also observed for relaxation and pain-free existence
408	when compared to the pool-REST condition ($ps < .05$). The opposite trend was found for
409	feelings of flow, increased empathy and compassion for others, and joy/happiness, such that
410	participants in the pool-REST condition tended to rate these items more positively than their
411	pool-REST preferred counterparts ($ps < .05$). The pool-REST group also rated feelings of
412	empathy and compassion for others more positively than their chair-REST counterparts ($p < .01$).
413	

- 414 Figure 6. Events Checklist. Note. Event anchors ranged from "Extremely Negative" to
- 415 "Extremely Positive" (anchors not shown). Asterisk (*) indicates significant group difference in

416 rating magnitude.



25

418	Regarding events that typically carry negative connotations, post-hoc comparisons
419	suggested that itchiness was experienced more negatively in the pool-REST and pool-REST
420	preferred conditions than the chair-REST condition ($ps < .05$). The pool-REST preferred
421	condition also rated feelings of intense fear and panic more negatively than the chair-REST
422	condition ($p = .045$). Interestingly, the pool-REST and pool-REST preferred conditions endorsed
423	experiencing feelings of detachment more positively than the chair-REST condition ($ps < .001$).
424	Stronger positive ratings were also observed in the pool-REST preferred condition than the
425	chair-REST condition for hallucinations ($p = .03$). Of note, the reports of hallucinations and
426	feelings of detachment occurred infrequently and tended to be described in neutral or positive
427	terms. For example, descriptions of hallucinations commonly mentioned visually experienced
428	colors and shapes, such as "Colorful visions; shapes, people, and characters," "Saw green,
429	crystal-like geometric shapes off and on (eyes were closed)," and "I experienced those colorful
430	flashes and dots similar to when you close your eyes and press lightly on your eyes." Feelings of
431	detachment were typically described using feelings of relaxation, weightlessness, and
432	disconnection from space and time, including: "I felt weightless. I felt like nothing else mattered.
433	It was just me," "Felt very relaxed like everything was far away," "A similar dozing detachment
434	as when you're half asleep for a really nice nap," and "I felt like I was in my own world and the
435	real world was frozen in time."
436	

The linear mixed model analysis also revealed a significant interaction between event and visit (F(214) = 1.40, p = .0001, $\eta_p^2 = .02$). Specifically, post-hoc analyses showed a weakening in the magnitude of positive events for all three interventions over the course of the study for the following events: serenity and peacefulness, appreciation for life, refreshment, relaxation, silent mind, pain-free existence, and feelings of flow (ps < .05).

26

442

443 Pool-REST Preferred

444	When allowed to select the frequency of sessions, the pool-REST preferred participants
445	chose to float at a frequency of once every 12 days, on average ($SD = 9.33$), and for an average
446	float duration of 75 minutes ($M = 75.4 \pm 29.4$ minutes). Exploratory analyses indicated that
447	session frequency and session duration were not significantly associated with baseline measures
448	of anxiety, depression, or anxiety sensitivity ($ps > .05$).
449	

- 450

Discussion

451 This study represents the first randomized controlled trial examining the feasibility, 452 tolerability, and safety of repeated sessions of floatation-REST in individuals with anxiety and 453 depression. We observed evidence of a favorable feasibility, tolerability, and safety profile for 454 the application of floatation-REST and chair-REST in this outpatient sample. Positive 455 experiences were endorsed more commonly than negative ones and were also rated at higher 456 levels of intensity, with no serious adverse events associated with any intervention. Taken 457 together, six sessions of floatation-REST appear feasible, well-tolerated, and safe in anxious and 458 depressed outpatient individuals.

Our primary outcome of adherence suggested that the feasibility of each form of REST, indexed via adherence to the allocated six-sessions, was adequate, ranging from 85-89% for the pool-REST conditions to 74% for the chair-REST condition. These levels of adherence are comparable to traditional behavioral interventions for anxiety and depression, whose treatment completion rates hover around 80% [16]. Each REST intervention was perceived to be moderately credible, with participants having positive expectations for symptom improvement.

465	The observed levels of credibility and expectancy beliefs are also consistent with those typically
466	seen for other behavioral interventions such as exposure therapy (range of credibility beliefs =
467	5.95-7.47, range of expectancy beliefs = 50.50-67.90; [21, 25, 29]).
468	The low dropout rates in this behavioral intervention study provides additional evidence
469	that repeated sessions of REST are well-tolerated. Dropout rates in the post randomization
470	setting prior to intervention onset were lowest for the pool interventions (4% dropout for pool-
471	REST, and 0% dropout for pool-REST preferred), while the chair-REST pretreatment dropout
472	rate was the highest (16%) and similar to those observed to cognitive behavioral therapy
473	(dropout rates ranging from 11-21%, [15]). Dropout rates during the administration of the REST
474	intervention (32% for chair-REST, 24% for pool-REST, and 16% for pool-REST preferred) were
475	also comparable to rates seen in non-pharmacological and pharmacological interventions such as
476	cognitive behavioral therapy (19-36%, [15]), meditation (33-44%, [30]), acceptance and
477	commitment therapy (15%, [31]), and antidepressant medications (37-49%, [32]).
478	Using session duration as an additional proxy of intervention tolerability, we saw very
479	few individuals in the pool-REST and chair-REST conditions who had a prescribed session
480	duration (i.e., 60 minutes) terminate early, with the majority of individuals utilizing their full
481	time allotment. For the pool-REST preferred group, who was given greater flexibility in session
482	duration (i.e., allowed to float for up to two hours), we observed longer average session
483	durations. Although the preferred condition was given an additional 60 minutes, they tended to
484	float about 20 minutes longer than the prescribed session conditions on average. Moreover,
485	session duration was unrelated to symptom severity at baseline, indicating that individuals with
486	higher levels of anxiety, depression, or anxiety sensitivity were no more or less likely to utilize
487	longer durations (i.e., in a self-medicating or symptom-dependent fashion). Taken together, these

28

findings may suggest that a 60-minute float is a suitable duration for future clinical trials in a clinically anxious and depressed sample. However, it remains to be determined whether there is additional utility of more time (e.g., 75 minutes), or alternatively, whether similar effects could be achieved with a shorter durations (e.g., 30 or 45 minutes).

492 The safety findings from this trial are consistent with previous single-session studies of 493 pool-REST and chair-REST which found few negative events and no serious adverse events [5, 494 7, 14]. Our study expands upon this work by showing a favorable safety profile across repeated 495 sessions of floatation-REST. We also demonstrated that positive experiences were endorsed 496 more commonly than negative ones, and at higher levels of intensity, in the mild-to-moderate 497 range. Importantly, while all three intervention groups consistently rated positive effects of the 498 intervention, the pool-REST groups tended to rate positive events more strongly, especially 499 regarding feelings of peace and tranquility. These findings provide support for the overall safety 500 of floatation-REST delivered in a pool or in a Zero Gravity chair setting. Moreover, the 501 comparable intensity ratings of many negative events but weaker ratings of positive events 502 within the chair-REST condition suggests that the chair is a suitable active comparator.

503 There were differential event profiles between the pool-REST conditions and the chair-504 REST condition, such that participants in the pool conditions reported stronger feelings of 505 tranquility (e.g., refreshment, peacefulness, serenity) than those in the chair-REST condition and 506 tended to rate itchiness and fear/panic more negatively than their chair-REST counterparts. The 507 most common negative events associated with pool-REST were itchiness and dry mouth, which 508 is consistent with our previous pilot study [5], and may be related to the high salt concentration 509 in the pools. In addition, several experiences that traditionally carry negative connotations, 510 including audiovisual hallucinations and feelings of detachment, tended to be described in a

29

511 positive light in the pool conditions. We do not believe the hallucinations reported by 512 participants in this study reflect hallucinations in the true sense of the term and do not consider 513 them indicative of psychosis-spectrum symptoms. Rather, these visual and auditory sensations 514 may be the result of the brain 'filling in the gaps,' i.e., generating sensory representations in the 515 face of absent exteroceptive input to the nervous system. Finally, the repeated nature of this 516 intervention allowed for a thorough examination of event profiles over time. An attenuation in 517 the magnitude of several positive events was observed at later sessions for all three interventions, 518 raising the possibility that the increased familiarity may reduce the novelty of the intervention 519 and the magnitude of positive events. 520 This investigation had several limitations that must be acknowledged. First, four 521 individuals in the chair-REST condition and one participant in the pool-REST condition 522 withdrew from the study after randomized allocation to their respective intervention and did not 523 complete the CEQ. These dropouts may suggest the presence of unmet expectations, particularly 524 for the individuals allocated to the chair-REST condition given that the largest dropout occurred 525 in this group. Alternatively, pre-intervention anticipatory anxiety could have played a role in 526 withdrawal, although we did not receive such reports from participants. To avoid the limitation 527 of missing data in the future, subsequent studies should aim to collect the CEQ measure 528 immediately following randomization. Another limitation of the current study is the modest 529 sample size. While our sample size was consistent with those used in previous floatation-REST 530 trials, larger groups may be needed for an adequately powered survival analysis for the purposes 531 of tolerability assessment. As such, the current study may be underpowered to detect meaningful 532 group differences in dropout rate. We examined six-session feasibility of REST whereas prior 533 clinical trials have typically used more sessions (e.g., 12). Thus, the measurement of feasibility

534	and tolerability during the employment of a larger number of sessions may be advisable in future
535	trials. Additionally, most of our sample was comprised of Caucasian, highly educated females,
536	thereby limiting generalizability claims to the broader population. Finally, due to the fact that
537	participants were financially compensated for their participation, we did not examine structural
538	aspects of feasibility relevant to the real-world delivery of behavioral therapies, including
539	financial and time commitments that might otherwise be important for treatment engagement.
540	
540	Conclusion
540 541	Conclusion The findings from this clinical trial suggests that six sessions of REST in a chair or pool
541	The findings from this clinical trial suggests that six sessions of REST in a chair or pool
541 542	The findings from this clinical trial suggests that six sessions of REST in a chair or pool environment are feasible, well-tolerated, and safe in clinically anxious and depressed outpatient

31

546 Funding

- 547 This research was supported by an award from the National Center for Complimentary and
- 548 Integrative Health (R34AT009889). The authors were also supported by the National Institute of
- 549 Mental Health (R01MH127225, K23MH112949 to SSK), National Institute of General Medical
- 550 Sciences Center Grant Award Number (1P20GM121312 to MPP, JSF, SSK), and The William
- 551 K. Warren Foundation. The funding sources had no role in the design and conduct of the study;
- 552 collection, management, analysis, and interpretation of the data; preparation, review, or approval
- 553 of the manuscript; or decision to submit the manuscript for publication.

554 Author Contributions

- 555 McKenna Garland: Writing—Original draft preparation, investigation, formal analysis,
- 556 visualization. Raminta Wilson: Investigation. Wesley Thompson: Writing—Review and editing.
- 557 Murray Stein: Writing—Review and editing. Martin Paulus: Writing—Review and editing,
- 558 supervision. Justin Feinstein: Conceptualization, methodology, resources, writing-review and
- 559 editing, supervision, project administration, funding acquisition. Sahib Khalsa:
- 560 Conceptualization, methodology, resources, writing—review and editing, supervision, project
- 561 administration, funding acquisition.

562 **Declaration of Conflicting Interests**

563 The authors declare that there are no conflicts of interests.

564 Acknowledgments

- 565 We would like to thank Henry Yeh, Jamie Rhudy, Emily Adamic, and Joel Greenshields for
- 566 consultation on coding and statistical matters. We would also like to acknowledge Laura
- 567 Garrison for her contributions to data collection. Finally, we would like to thank the custodial

568 staff at the Laureate Institute for Brain Research for their diligence in maintaining the floatation-

569 REST and chair-REST facilities.

570	References				
571	1. Suedfeld P, Coren S. Perceptual isolation, sensory deprivation, and rest: Moving				
572	introductory psychology texts out of the 1950s. Canadian Psychology/Psychologie canadienne.				
573	1989;30(1):17.				
574	2. Rossi AM. General methodological considerations. Sensory deprivation: Fifteen years of				
575	research. 1969:16-46.				
576	3. Lilly JC, Shurley JT. Experiments in solitude, in maximum achievable physical isolation				
577	with water suspension, of intact healthy persons. Psychophysiological aspects of space flight.				
578	1961:238-47.				
579	4. Shurley JT. Profound experimental sensory isolation. American Journal of Psychiatry.				
580	1960;117(6):539-45.				
581	5. Feinstein JS, Khalsa SS, Yeh HW, Wohlrab C, Simmons WK, Stein MB, et al.				
582	Examining the short-term anxiolytic and antidepressant effect of Floatation-REST. PLoS One.				
583	2018;13(2):e0190292. Epub 20180202. doi: 10.1371/journal.pone.0190292. PubMed PMID:				
584	29394251; PubMed Central PMCID: PMCPMC5796691.				
585	5. Al Zoubi O, Misaki M, Bodurka J, Kuplicki R, Wohlrab C, Schoenhals WA, et al. Taking				
586	he body off the mind: Decreased functional connectivity between somatomotor and default-				
587	node networks following Floatation-REST. Hum Brain Mapp. 2021;42(10):3216-27. Epub				
588	20210409. doi: 10.1002/hbm.25429. PubMed PMID: 33835628; PubMed Central PMCID:				
589	РМСРМС8193533.				
590	7. Khalsa SS, Moseman SE, Yeh H-W, Upshaw V, Persac B, Breese E, et al. Reduced				
591	environmental stimulation in anorexia nervosa: an early-phase clinical trial. Frontiers in				
592	psychology. 2020:2534.				

593	8.	Solutions FT, LLC FO. State of the Float Industry Report. Float Tank Solutions; 2020.				
594	9.	Jonsson K, Kjellgren A. Promising effects of treatment with flotation-REST (restricted				
595	environmental stimulation technique) as an intervention for generalized anxiety disorder (GAD):					
596	a randomized controlled pilot trial. BMC complementary and alternative medicine. 2016;16(1):1-					
597	12.					
598	10.	Bood SÅ, Sundequist U, Kjellgren A, Nordström G, Norlander T. Effects of flotation rest				
599	(restricted environmental stimulation technique) on stress related muscle pain: are 33 flotation					
600	sessions more effective than 12 sessions? Social Behavior and Personality: an international					
601	journal. 2007;35(2):143-56.					
602	11.	Feinstein JS, Khalsa SS, Yeh H, Al Zoubi O, Arevian AC, Wohlrab C, et al. The				
603	elicitation of relaxation and interoceptive awareness using floatation therapy in individuals with					
604	high anxiety sensitivity. Biological psychiatry: cognitive neuroscience and neuroimaging.					
605	2018;3(6):555-62.					
606	12.	Lann MA, Martin A. An unusual death involving a sensory deprivation tank. Journal of				
607	forensic sciences. 2010;55(6):1638-40.					
608	13.	Norlander T, Kjellgren A, Archer T. The experience of flotation-REST as a function of				
609	setting and previous experience of altered state of consciousness. Imagination, Cognition and					
610	Personality. 2000;20(2):161-78.					
611	14.	Forgays DG, Belinson MJ. Is flotation isolation a relaxing environment? Journal of				
612	Enviro	onmental Psychology. 1986;6(1):19-34.				
613	15.	Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive				
614	behavioral therapy: Magnitude, timing, and moderators. Journal of Consulting and Clinical					
615	Psychology. 2015;83(6):1108.					

616	16.	Swift JK, Greenberg RP	, Tompkins	s KA, Parkin SR.	Treatment refusal	and premature

- 617 termination in psychotherapy, pharmacotherapy, and their combination: A meta-analysis of head-
- 618 to-head comparisons. Psychotherapy. 2017;54(1):47.
- 619 17. Victor TA, Khalsa SS, Simmons WK, Feinstein JS, Savitz J, Aupperle RL, et al. Tulsa
- 620 1000: a naturalistic study protocol for multilevel assessment and outcome prediction in a large
- 621 psychiatric sample. BMJ open. 2018;8(1):e016620.
- 622 18. Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA, et al.
- 623 Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety
- 624 Severity and Impairment Scale (OASIS). Journal of affective disorders. 2009;112(1-3):92-101.
- 625 19. Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, et al. Robust
- 626 dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity
- 627 Index-3. Psychological assessment. 2007;19(2):176.
- 628 20. Kroenke K, Spitzer RL, Williams JB. The PHQ□9: validity of a brief depression severity
 629 measure. Journal of general internal medicine. 2001;16(9):606-13.
- 630 21. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy
- 631 questionnaire. Journal of behavior therapy and experimental psychiatry. 2000;31(2):73-86.
- 632 22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 633 data capture (REDCap)—a metadata-driven methodology and workflow process for providing
- translational research informatics support. Journal of biomedical informatics. 2009;42(2):377-81.
- 635 23. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
- 636 consortium: Building an international community of software platform partners. Journal of
- 637 biomedical informatics. 2019;95:103208.

36

- 638 24. Kazdin AE. Therapy outcome questions requiring control of credibility and treatment-
- 639 generated expectancies. Behavior Therapy. 1979;10(1):81-93.
- 640 25. Thompson-Hollands J, Bentley KH, Gallagher MW, Boswell JF, Barlow DH. Credibility
- and outcome expectancy in the unified protocol: Relationship to outcomes. Journal of
- Experimental Psychopathology. 2014;5(1):72-82.
- 643 26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of
- the American statistical association. 1958;53(282):457-81.
- 645 27. Team R. RStudio: Integrated Devleopment for R. . Boston, MA: RStudio, PBC; 2020.
- 646 28. Sheehan D, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M. Mini
- 647 international neuropsychiatric interview. Tampa: University of South Florida. 1994.
- 648 29. Arch JJ, Twohig MP, Deacon BJ, Landy LN, Bluett EJ. The credibility of exposure
- therapy: Does the theoretical rationale matter? Behaviour research and therapy. 2015;72:81-92.
- 650 30. Krisanaprakornkit T, Sriraj W, Piyavhatkul N, Laopaiboon M. Meditation therapy for
- anxiety disorders. Cochrane Database of Systematic Reviews. 2006;(1).
- 652 31. Ong CW, Lee EB, Twohig MP. A meta-analysis of dropout rates in acceptance and
- 653 commitment therapy. Behaviour research and therapy. 2018;104:14-33.
- 654 32. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug
- reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Current
- medical research and opinion. 2006;22(9):1825-37.